These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17187506)

  • 21. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV resistance-testing information on web.
    AIDS Treat News; 2000 Feb; (No 337):6. PubMed ID: 11367209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
    Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
    Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.
    Read P; Costelloe S; Mullen J; O'Shea S; Lyons F; Hay P; Welch J; Larbalestier N; Taylor G; de Ruiter A
    HIV Med; 2008 Aug; 9(7):448-51. PubMed ID: 18840150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-drug resistant HIV-1.
    Omrani AS; Pillay D
    J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment-for-prevention: clinical considerations.
    Lockman S; Sax P
    Curr Opin HIV AIDS; 2012 Mar; 7(2):131-9. PubMed ID: 22227588
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sanctuary sites in HIV-1 infection.
    Hoetelmans RM
    Antivir Ther; 1998; 3 Suppl 4():13-7. PubMed ID: 10723504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda.
    Dieffenbach CW
    Curr Opin HIV AIDS; 2012 Mar; 7(2):106-10. PubMed ID: 22227584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV resistance testing: a new clinical tool.
    Jorden VS; Paul SM
    N J Med; 2000 Oct; 97(10):33-8. PubMed ID: 11064565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
    Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
    J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacogenomics of HIV therapy.
    Pirmohamed M; Back DJ
    Pharmacogenomics J; 2001; 1(4):243-53. PubMed ID: 11908767
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of antiretroviral drugs to prevent sexual transmission of HIV.
    Cohen MS; Hosseinipour M; Kashuba A; Butera S
    Curr Clin Top Infect Dis; 2002; 22():214-51. PubMed ID: 12520656
    [No Abstract]   [Full Text] [Related]  

  • 36. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 37. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of HIV protease inhibitor resistance in treatment-naive populations in the united states.
    Hicks C
    AIDS Read; 2005 Dec; 15(12):683-6, 689-90. PubMed ID: 16355598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of drug resistance-related mutations among HIV-1s in Japan.
    Sugiura W; Matsuda M; Abumi H; Yamada K; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takada N; Kakishita E; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Feb; 52(1):21-2. PubMed ID: 10808258
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations.
    Wang K; Samudrala R; Mittler JE
    J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.